Excipient (milk powder)

Biologic

UUniversidad Complutense de Madrid

Excipient (milk powder) is one of 5 biologic programs targeting Mastitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastitisActive, not recruiting

MastitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Mastitis

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Approved

—2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—3

Beta-Lactam Antibiotic

UUniversity Hospital, Ghent

Phase 3

1 4

Lactobacillus Reuteri CR20

UUniversidad Complutense de Madrid

Phase 2

2 5

Excipient (milk powder)

UUniversidad Complutense de Madrid

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mastitis1 trial

Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization

Unknown status·UUniversidad Complutense de Madrid·Phase 1/2·NCT01505361·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Excipient (milk powder). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Excipient (milk powder) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Excipient (milk powder). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Complutense de Madrid company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: UUniversidad Complutense de Madrid

Excipient (milk powder)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mastitis1 trial

References

Drug Info

Quick Facts

Related News